Spurdle AB - Search Results

1

Gynecological conditions and the risk of endometrial cancer.

Rowlands IJ, Nagle CM, Spurdle AB, Webb PM; Australian National Endometrial Cancer Study Group; Australian Ovarian Cancer Study Group. Rowlands IJ, et al. Among authors: spurdle ab. Gynecol Oncol. 2011 Dec;123(3):537-41. doi: 10.1016/j.ygyno.2011.08.022. Epub 2011 Sep 16. Gynecol Oncol. 2011. PMID: 21925719

2

CYP17 promotor polymorphism and ovarian cancer risk.

Spurdle AB, Chen X, Abbazadegan M, Martin N, Khoo SK, Hurst T, Ward B, Webb PM, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 May 1;86(3):436-9. doi: 10.1002/(sici)1097-0215(20000501)86:3<436::aid-ijc21>3.0.co;2-a. Int J Cancer. 2000. PMID: 10760835 Free article.

3

Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer.

Spurdle AB, Webb PM, Chen X, Martin NG, Giles GG, Hopper JL, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 Sep 1;87(5):637-43. Int J Cancer. 2000. PMID: 10925355 Free article.

4

Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Carcinogenesis. 2001 Jan;22(1):67-72. doi: 10.1093/carcin/22.1.67. Carcinogenesis. 2001. PMID: 11159743

5

The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer.

Spurdle AB, Purdie DM, Webb PM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Mol Carcinog. 2001 Jan;30(1):71-8. doi: 10.1002/1098-2744(200101)30:1<71::aid-mc1015>3.0.co;2-9. Mol Carcinog. 2001. PMID: 11255266

6

No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Carcinogenesis. 2001 May;22(5):717-21. doi: 10.1093/carcin/22.5.717. Carcinogenesis. 2001. PMID: 11323389

7

The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years.

Spurdle AB, Hopper JL, Chen X, Dite GS, Cui J, McCredie MR, Giles GG, Ellis-Steinborner S, Venter DJ, Newman B, Southey MC, Chenevix-Trench G. Spurdle AB, et al. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):413-6. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 11927503

8

The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.

Spurdle AB, Hopper JL, Chen X, McCredie MR, Giles GG, Venter DJ, Southey MC, Chenevix-Trench G. Spurdle AB, et al. Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):439-43. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12010857

9

Prohibitin 3' untranslated region polymorphism and breast cancer risk in Australian women.

Spurdle AB, Hopper JL, Chen X, McCredie MR, Giles GG, Newman B, Chenevix-Trench G. Spurdle AB, et al. Lancet. 2002 Sep 21;360(9337):925-6. doi: 10.1016/S0140-6736(02)11043-9. Lancet. 2002. PMID: 12354477

10

The prohibitin 3' untranslated region polymorphism is not associated with risk of ovarian cancer.

Spurdle AB, Purdie DM, Chen X, Chenevix-Trench G. Spurdle AB, et al. Gynecol Oncol. 2003 Jul;90(1):145-9. doi: 10.1016/s0090-8258(03)00193-8. Gynecol Oncol. 2003. PMID: 12821355

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

461 results

Search Page